Zai Lab
Heather Embree has extensive experience in the biotechnology and pharmaceutical industry. Heather is currently working at Zai Lab as the Vice President of R&D Strategic Operations. Prior to this, they held a position as a Member at Chief. Before joining Zai Lab, Heather held multiple roles at Allogene Therapeutics, including Vice President of Program Management and Head of Portfolio Management. Heather also worked at Lentigen Technology Inc., where they served as Director of Commercial Operations. Heather's career began at Lentigen Corporation, where they held various positions, including Director of Operations and Interim Director of Quality. Additionally, they worked at Lonza and MeadWestvaco in research and quality assurance roles. Heather Embree's work experience spans over 20 years and showcases their expertise in program management, portfolio management, and operations in the biotechnology sector.
Heather Embree holds a Bachelor of Science degree in Chemical and Biochemical Engineering from the University of Maryland Baltimore County. Heather also obtained a Master of Science degree in the same field from the same university.
This person is not in any offices
Zai Lab
5 followers
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.